Linden Wolfgang, Andrea Vodermaier A, McKenzie Regina, Barroetavena Maria C, Yi Dahyun, Doll Richard
Department of Psychology, University of British Columbia, Vancouver, BC, Canada.
Health Qual Life Outcomes. 2009 Feb 24;7:16. doi: 10.1186/1477-7525-7-16.
We have previously reported on the development of a cancer-specific screening instrument for anxiety and depression (PSSCAN). No information on cut-off scores or their meaning for diagnosis was available when PSSCAN was first described. Needed were additional analyses to recommend empirically justified cut-off scores as well as data norms for healthy adult samples so as to lend meaning to the recommended cut-off scores.
We computed sensitivity/specificity indices based on a sample of 101 cancer patients who had provided PSSCAN data on anxiety and depression and who had completed another standardized instrument with strong psychometrics. Next, we compared mean scores for four samples with known differences in health status, a healthy community sample (n = 561), a sample of patients with a representative mix of cancer subtypes (n = 570), a more severely ill sample of in-patients with cancer (n = 78), and a community sample with a chronic illness other than cancer (n = 85).
Sensitivity/specificity analyses revealed that an excellent balance of sensitivity/specificity was achievable with 92%/98% respectively for clinical anxiety and 100% and 86% respectively for clinical depression. Newly diagnosed patients with cancer were no more anxious than healthy community controls but showed elevations in depression scores. Both, patients with chronic illness other than cancer and those with longer-standing cancer diagnoses revealed greater levels of distress than newly diagnosed cancer patients or healthy adult controls.
These additional data on criterion validity and community versus patient norms for PSSCAN serve to enhance its utility for clinical practice.
我们之前报道了一种针对焦虑和抑郁的癌症特异性筛查工具(PSSCAN)的开发情况。首次描述PSSCAN时,没有关于临界值分数或其诊断意义的信息。需要进行额外分析,以推荐基于经验的合理临界值分数以及健康成人样本的数据规范,从而使推荐的临界值分数具有意义。
我们基于101名癌症患者的样本计算了敏感性/特异性指数,这些患者提供了关于焦虑和抑郁的PSSCAN数据,并完成了另一种具有强大心理测量学特性的标准化工具。接下来,我们比较了四个健康状况已知不同的样本的平均分数,一个健康社区样本(n = 561)、一个具有代表性癌症亚型组合的患者样本(n = 570)、一个病情更严重的癌症住院患者样本(n = 78)以及一个患有非癌症慢性病的社区样本(n = 85)。
敏感性/特异性分析显示,临床焦虑的敏感性/特异性分别达到92%/98%,临床抑郁分别达到100%和86%,可实现极佳的敏感性/特异性平衡。新诊断的癌症患者并不比健康社区对照组更焦虑,但抑郁得分有所升高。患有非癌症慢性病的患者和癌症诊断时间较长的患者都比新诊断的癌症患者或健康成人对照组表现出更高的痛苦水平。
这些关于PSSCAN的效标效度以及社区与患者规范的额外数据有助于提高其在临床实践中的效用。